Biogen Expects FY23 Adjusted EPS Of $14.50-$15.00 Compared To Prior Guidance Of $15.00-$16.00 And Consensus Of $15.23
Portfolio Pulse from Benzinga Newsdesk
Biogen has revised its FY23 adjusted EPS guidance to $14.50-$15.00, down from the previous guidance of $15.00-$16.00. This is also below the consensus estimate of $15.23.
November 08, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen's revised FY23 adjusted EPS guidance is lower than previously expected, which could negatively impact the company's stock price in the short term.
Biogen's revised FY23 adjusted EPS guidance is lower than both its previous guidance and the consensus estimate. This suggests that the company's earnings may not meet expectations, which could lead to a decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100